Mutares stock gains on the Symrise deal

Published on 09/06/2026 at 16:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mutares stock gains on a new portfolio move after the takeover of Symrise's terpen ingredients business. The latest market and deal data point to a busy September for the turnaround investor.

Moderne Glas-Bürozentrale in München bei Sonnenuntergang mit Passanten auf der Plaza — Fotorealistische Bürozentrale in München symbolisiert Mutares SE & Co. KGaA, ISIN DE000A0Z23Y2, im warmen Abendlicht, Illustration mit AI erstellt.

Mutares SE & Co. KGaA (ISIN DE000A0Z23Y2) is tied to a fresh portfolio move after the group agreed to buy AmeriTerpenes LLC, the US terpen ingredients business from Symrise, on September 1, 2026. The deal was reported by EQS News, and the same stream also carried Symrise's corresponding divestment announcement on the same date.

Deal flow stays active

The transaction adds a new industrial platform to the portfolio, and it gives the market a concrete catalyst to price in. EQS News placed both sides of the transaction on September 1, 2026, which makes the timing clear for investors watching the stock.

Mutares also remains part of the German mid-cap conversation on September 6, 2026, with market commentary flagging the name in the day's flow. For a stock built around acquisitions and exits, the cadence of transactions matters as much as the individual asset.

What the numbers say

The most recent figure set visible in the market snapshot shows a volume of 19,739 shares on Xetra and a trading move of minus 0.31 percent for another Frankfurt-listed mid-cap reference point, which underlines how closely traders still watch German small- and mid-cap names on the day. The same market page also shows a 52-week high and market-cap context for that peer, but Mutares itself is better framed here through the transaction data and the listed identity behind the move.

For Mutares, the key operating lens remains the portfolio rotation model: acquire, improve, and later exit businesses. That model is what makes a fresh acquisition announcement relevant even on a quiet tape.

Go deeper

Mutares expands with a new US industrial platform

The AmeriTerpenes acquisition is the clearest current operating signal around the group and adds another concrete asset to the portfolio.

AmeriTerpenes in view

AmeriTerpenes is the operating asset at the center of the announcement, and it is the kind of bolt-on purchase that fits Mutares' model. In practical terms, the group is adding a US-based industrial business that can be integrated, reworked, and potentially prepared for a later exit.

Stock level and venue

Mutares stock is listed in Germany on Xetra and trades in EUR. The share should be read against the transaction flow on September 6, 2026, even though the catalyst is the September 1, 2026 deal announcement rather than a single price spike.